查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618546

腰椎間盤退化性疾病市場：治療方法、給藥途徑和最終用戶分類 - 全球預測 2025-2030

Lumbar Degenerative Disc Disease Market by Treatment (Epidural Steroid Injections (ESIs), Over-the-counter (OTC) Pain Medications, Therapy Devices), Route of Administration (Injectables, Oral), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

腰椎退化性疾病市場價值2023年為7.4458億美元，預計到2024年將達到7.9633億美元，複合年成長率為7.15%，到2030年預計將達到12.0776億美元。

腰椎退化性疾病（LDDD）是一種以腰椎間盤劣化為特徵的疾病，導致慢性疼痛。這種疾病在老年人和久坐人群中的盛行率不斷增加，增加了對有效治療方法和技術的需求。市場範圍包括外科介入、生物療法以及再生醫學和微創手術等新技術解決方案。背部和頸部疼痛是就醫和缺勤的首要原因之一，推動了從醫院到門診手術中心等醫療領域的應用。對個人化和具有成本效益的治療的需求正在進一步指導最終用途，重點是以患者為中心的護理模式。關鍵的成長要素包括脊椎設備和再生醫學的技術進步、醫療保健支出的增加以及患者對可用治療方法的認知的提高。治療機會在於採用再生療法，例如創新的生物材料和基於幹細胞的產品，這些產品具有侵入性較小且有效的治療潛力。開發商應利用推廣非手術治療來緩解疼痛和阻止疾病進展的趨勢，同時擴大其在醫療基礎設施快速發展的新興市場的地理影響力。相反，市場成長的限制包括高昂的手術成本和與新醫療技術相關的監管複雜性。來自物理療法和脊骨神經醫學等替代療法的競爭也可能是一個挑戰。需要創新的領域包括開發下一代生技藥品、用於更好診斷的先進成像以及用於連續監測的患者友好型穿戴式技術。公司應該投資研究合作和病患教育，以提高對新治療方法的接受度。該市場本質上仍然充滿活力，由於新進入者的強大管道以及技術進步和全球人口老化導致的需求增加，具有巨大的成長空間。

主要市場統計
基準年[2023] 74458萬美元
預計年份 [2024] 7.9633億美元
預測年份 [2030] 1,207.76 百萬美元
複合年成長率（%） 7.15%

市場動態：揭示快速發展的腰椎退化性疾病市場的關鍵市場洞察

腰椎退化性疾病市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 腰椎間盤退化性疾病的盛行率不斷擴大
    • 進行宣傳活動並加強有關 LDDD 的教育
  • 市場限制因素
    • 報銷限制
  • 市場機會
    • 持續研究和開發引入新的 LDDD 治療和診斷
    • 政府對 LDDD 治療商業化的有利核准
  • 市場問題
    • 手術和藥物開發的複雜性

波特五力：駕馭腰椎退化性疾病市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腰椎退化性疾病市場的外部影響

外部宏觀環境因素在塑造腰椎退化性疾病市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解腰椎間盤退化性疾病市場的競爭格局

腰椎間盤退化性疾病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣：腰椎間盤退化性疾病市場供應商的績效評估

FPNV 定位矩陣是評估腰椎退化性疾病市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製腰椎退化性疾病市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對腰椎退化性疾病市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

它也回答重要問題，幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 腰退化性疾病的盛行率不斷增加
      • 擴大 LDDD 的宣傳活動和教育
    • 抑制因素
      • 退款數量有限
    • 機會
      • 持續研究和開發，為 LDDD 引入新的治療方法和診斷方法
      • 政府對 LDDD 藥物商業化的有利核准
    • 任務
      • 手術和藥物開發的複雜性
  • 市場區隔分析
    • 治療：增加使用硬膜外類固醇注射 (ESI) 來治療腰椎退化性疾病
    • 最終用戶：對腰椎退化性疾病治療的患者診斷、治療和管理的需求不斷增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章腰椎間盤退化性疾病市場：依治療分類

  • 介紹
  • 硬脊膜外類固醇注射 (ESI)
  • 非處方止痛藥
    • 乙醯胺酚
    • 抗發炎藥
    • 皮質類固醇
    • 肌肉鬆弛劑
    • 藥品
  • 治療設備

第7章腰椎間盤退化性疾病市場：依給藥途徑

  • 介紹
  • 注射
  • 口服

第8章腰椎間盤退化性疾病市場：依最終用戶分類

  • 介紹
  • 學術研究中心
  • 醫院/診所
  • 專科診所

第9章北美及南美腰退化性疾病市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區腰椎間盤退化性疾病市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東與非洲腰椎間盤退化性疾病市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准ReGelTec 的 HYDRAFIL 系統用於治療腰椎退化性疾病
    • RIT 研究人員獲得 NIH津貼，用於 CRISPR 增強幹細胞療法治療腰椎退化性疾病
    • Companion Spine 透過策略收購 Backbone SAS 推動全球脊椎醫學發展
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AnGes MG, Inc.
  • AxioMed LLC
  • B. Braun SE
  • Baxter International Inc.
  • Benvenue Medical, Inc.
  • Biopharm GmbH
  • Boston Scientific Corporation
  • Centinel Spine, LLC
  • Cerapedics Inc.
  • ChoiceSpine
  • DePuy Synthes by Medical Device Business Services, Inc.
  • Globus Medical, Inc.
  • Kolon TissueGene Inc.
  • Kuros Biosciences
  • Lineage Cell Therapeutics, Inc.
  • Medtronic plc
  • NLC Ventures Netherlands BV
  • Notogen, Inc.
  • Orthofix Medical Inc.
  • RTI Surgical Holdings, Inc.
  • Stryker Corporation
  • Ulrich Medical USA Inc.
  • Veritas Health, LLC
  • Xtant Medical Holdings, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-D566A980152E

The Lumbar Degenerative Disc Disease Market was valued at USD 744.58 million in 2023, expected to reach USD 796.33 million in 2024, and is projected to grow at a CAGR of 7.15%, to USD 1,207.76 million by 2030.

Lumbar Degenerative Disc Disease (DDD) is a condition characterized by the deterioration of the intervertebral discs in the lumbar spine, causing chronic pain. The rising prevalence of this ailment among aging populations and sedentary individuals propels demand for effective treatments and technologies. The market scope encompasses surgical interventions, biological therapies, and emerging technology-based solutions like regenerative medicine and minimally invasive procedures. A significant necessity drives this market; back and neck pain is among the top reasons for physician visits and absenteeism from work, fostering applications in healthcare sectors from hospitals to outpatient surgical centers. The need for personalized, cost-effective treatments further guides end-use by focusing on patient-centric care models. Key growth factors include technological advancements in spinal devices and regenerative medicine, increasing healthcare expenditures, and growing awareness of available treatments among patients. Opportunities lie in the adoption of innovative biomaterials and regenerative therapies, like stem cell-based products, which show potential for less invasive and more effective treatments. Commercial entities should capitalize on trends promoting non-surgical therapies designed to alleviate pain and halt the disease's progression while broadening their geographical presence in emerging markets where healthcare infrastructure is developing rapidly. Conversely, market growth constraints include high procedure costs and the regulatory complexities associated with new medical technologies. Competition from alternative treatments such as physical therapy and chiropractic interventions may also pose challenges. Areas ripe for innovation include the development of next-generation biologics, advanced imaging for better diagnosis, and patient-friendly, wearable technologies for continuous monitoring. Businesses should invest in research partnerships and patient education to foster acceptance of novel therapies. The market maintains a dynamic nature with a robust pipeline for new entrants and substantial room for growth, driven by both technological advancements and a demand increase prompted by an aging global population.

KEY MARKET STATISTICS
Base Year [2023] USD 744.58 million
Estimated Year [2024] USD 796.33 million
Forecast Year [2030] USD 1,207.76 million
CAGR (%) 7.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lumbar Degenerative Disc Disease Market

The Lumbar Degenerative Disc Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of lumbar degenerative disc disease
    • Rising awareness campaigns and education about LDDD
  • Market Restraints
    • Limited availability of reimbursement
  • Market Opportunities
    • Ongoing R&D for introducing new LDDD treatments and diagnosis
    • Favorable government approvals for LDDD medicine commercialization
  • Market Challenges
    • Complexity in surgical procedures and medicine development

Porter's Five Forces: A Strategic Tool for Navigating the Lumbar Degenerative Disc Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lumbar Degenerative Disc Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lumbar Degenerative Disc Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lumbar Degenerative Disc Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lumbar Degenerative Disc Disease Market

A detailed market share analysis in the Lumbar Degenerative Disc Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lumbar Degenerative Disc Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lumbar Degenerative Disc Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lumbar Degenerative Disc Disease Market

A strategic analysis of the Lumbar Degenerative Disc Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lumbar Degenerative Disc Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AnGes MG, Inc., AxioMed LLC, B. Braun SE, Baxter International Inc., Benvenue Medical, Inc., Biopharm GmbH, Boston Scientific Corporation, Centinel Spine, LLC, Cerapedics Inc., ChoiceSpine, DePuy Synthes by Medical Device Business Services, Inc., Globus Medical, Inc., Kolon TissueGene Inc., Kuros Biosciences, Lineage Cell Therapeutics, Inc., Medtronic plc, NLC Ventures Netherlands B.V., Notogen, Inc., Orthofix Medical Inc., RTI Surgical Holdings, Inc., Stryker Corporation, Ulrich Medical USA Inc., Veritas Health, LLC, Xtant Medical Holdings, Inc., and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Lumbar Degenerative Disc Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Epidural Steroid Injections (ESIs), Over-the-counter (OTC) Pain Medications, and Therapy Devices. The Over-the-counter (OTC) Pain Medications is further studied across Acetaminophen, Anti-inflammatories, Corticosteroids, Muscle Relaxants, and Narcotics.
  • Based on Route of Administration, market is studied across Injectables and Oral.
  • Based on End-Users, market is studied across Academic Research Centers, Hospitals & Clinics, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of lumbar degenerative disc disease
      • 5.1.1.2. Rising awareness campaigns and education about LDDD
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of reimbursement
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D for introducing new LDDD treatments and diagnosis
      • 5.1.3.2. Favorable government approvals for LDDD medicine commercialization
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in surgical procedures and medicine development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Rising usage of epidural steroid injections (ESIs) for management of lumbar degenerative disc disease
    • 5.2.2. End-Users: Increasing need for lumbar degenerative disc disease treatment for diagnosing, treating, and managing patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lumbar Degenerative Disc Disease Market, by Treatment

  • 6.1. Introduction
  • 6.2. Epidural Steroid Injections (ESIs)
  • 6.3. Over-the-counter (OTC) Pain Medications
    • 6.3.1. Acetaminophen
    • 6.3.2. Anti-inflammatories
    • 6.3.3. Corticosteroids
    • 6.3.4. Muscle Relaxants
    • 6.3.5. Narcotics
  • 6.4. Therapy Devices

7. Lumbar Degenerative Disc Disease Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectables
  • 7.3. Oral

8. Lumbar Degenerative Disc Disease Market, by End-Users

  • 8.1. Introduction
  • 8.2. Academic Research Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Clinics

9. Americas Lumbar Degenerative Disc Disease Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lumbar Degenerative Disc Disease Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lumbar Degenerative Disc Disease Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Clears ReGelTec's HYDRAFIL System for Treatment of Lumbar Degenerative Disc Disease
    • 12.3.2. RIT Researchers Awarded NIH Grant to CRISPR-Enhanced Stem Cell Therapy for Lumbar Degeneration
    • 12.3.3. Companion Spine Advances Global Spine Health with Strategic Acquisition of Backbone SAS
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AnGes MG, Inc.
  • 3. AxioMed LLC
  • 4. B. Braun SE
  • 5. Baxter International Inc.
  • 6. Benvenue Medical, Inc.
  • 7. Biopharm GmbH
  • 8. Boston Scientific Corporation
  • 9. Centinel Spine, LLC
  • 10. Cerapedics Inc.
  • 11. ChoiceSpine
  • 12. DePuy Synthes by Medical Device Business Services, Inc.
  • 13. Globus Medical, Inc.
  • 14. Kolon TissueGene Inc.
  • 15. Kuros Biosciences
  • 16. Lineage Cell Therapeutics, Inc.
  • 17. Medtronic plc
  • 18. NLC Ventures Netherlands B.V.
  • 19. Notogen, Inc.
  • 20. Orthofix Medical Inc.
  • 21. RTI Surgical Holdings, Inc.
  • 22. Stryker Corporation
  • 23. Ulrich Medical USA Inc.
  • 24. Veritas Health, LLC
  • 25. Xtant Medical Holdings, Inc.
  • 26. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. LUMBAR DEGENERATIVE DISC DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LUMBAR DEGENERATIVE DISC DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LUMBAR DEGENERATIVE DISC DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUMBAR DEGENERATIVE DISC DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUMBAR DEGENERATIVE DISC DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY EPIDURAL STEROID INJECTIONS (ESIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY MUSCLE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY NARCOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY THERAPY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. LUMBAR DEGENERATIVE DISC DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. LUMBAR DEGENERATIVE DISC DISEASE MARKET, FPNV POSITIONING MATRIX, 2023